Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (115)	6/9/1998 3:18:00 PM
From: Richard Haugland	Respond to of 184

SANG Upgrade (copied from Yahoo Board) Here's comments on uptick from Motley Fool lunchtime today: Organ transplant pharmaceutical developer Sangstat Medical Corp. (Nasdaq: SANG) gained $2 1/4 to $27 11/16 after naming Jean-Jacques Bienaime president and COO. Salomon Smith Barney started coverage of the company with a "buy" rating and set a 12-month price target of $60 per share.

To: Doug who wrote (115)	6/9/1998 3:28:00 PM
From: Richard Haugland	Read Replies (1) \| Respond to of 184

Doug, sorry I am zero for five on your questions. Although I am a chemist and business owner, I don't know the economics of the pharmaceutical or medical fields. I would expect manufacturing margins to eventually be very high like most drugs but there are a lot of costs to amortize. From what I understand about liability, the patients are always required to sign informed consent forms to take care of much of this and the treatments that SANG is developing are far from guaranteed to be successful in all cases. From what I read on the SANG Novartis board, it is far more likely that SANG will be sued by Novartis: messages.yahoo.com@m2.yahoo.com